3 results
Approved WMOCompleted
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
Approved WMOCompleted
Primary: efficacy and safety of the addition of UMEC 62.5mcg once daily to ICS/LABA therapy, compared with placebo over 12 weeks in subjects with COPD.Secondary: effect of the addition of UMEC to ICS/LABA therapy on COPD-related health status…
Approved WMOPending
Main study: to examine whether low dose GC therapy is more effective via the oral route compared to the parenteral route.Dose finding study (pilot study): to examine which oral GC dose is needed for a noticeable decrease in Erythrocyte Sedimentation…